DexCom Stock Forecast, Price & News

DexCom (NASDAQ:DXCM) Frequently Asked Questions

Is DexCom a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DexCom stock.
View analyst ratings for DexCom or view top-rated stocks.

What stocks does MarketBeat like better than DexCom?

Wall Street analysts have given DexCom a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but DexCom wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is DexCom's next earnings date?

DexCom is scheduled to release its next quarterly earnings announcement on Tuesday, October 26th 2021.
View our earnings forecast for DexCom.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) posted its earnings results on Thursday, July, 29th. The medical device company reported $0.76 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.43 by $0.33. The medical device company had revenue of $595.10 million for the quarter, compared to analyst estimates of $548.02 million. DexCom had a trailing twelve-month return on equity of 16.17% and a net margin of 24.45%.
View DexCom's earnings history.

How has DexCom's stock been impacted by COVID-19 (Coronavirus)?

DexCom's stock was trading at $252.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DXCM shares have increased by 122.1% and is now trading at $560.74.
View which stocks have been most impacted by COVID-19.

What guidance has DexCom issued on next quarter's earnings?

DexCom updated its FY 2021 earnings guidance on Thursday, August, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.35 billion-$2.40 billion, compared to the consensus revenue estimate of $2.34 billion.

What price target have analysts set for DXCM?

15 Wall Street analysts have issued 12-month target prices for DexCom's shares. Their forecasts range from $438.00 to $650.00. On average, they expect DexCom's stock price to reach $507.47 in the next year. This suggests that the stock has a possible downside of 9.5%.
View analysts' price targets for DexCom or view top-rated stocks among Wall Street analysts.

Who are DexCom's key executives?

DexCom's management team includes the following people:

• Kevin Ronald Sayer, Chairman, President & Chief Executive Officer
• Jereme M Sylvain, SVP-Finance, Chief Financial & Accounting Officer (LinkedIn Profile)
• Andrew K. Balo, EVP-Clinical Affairs, Regulatory Strategy (LinkedIn Profile)
• Jacob S. Leach, Chief Technology Officer & Executive VP
• Shelly R. Selvaraj, Senior Vice President-Information Technology

What is Kevin Sayer's approval rating as DexCom's CEO?

347 employees have rated DexCom CEO Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among DexCom's employees.

Who are some of DexCom's key competitors?

Some companies that are related to DexCom include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Edwards Lifesciences (EW), Becton, Dickinson and (BDX), Boston Scientific (BSX), IDEXX Laboratories (IDXX), ResMed (RMD), Baxter International (BAX), STERIS (STE), Insulet (PODD), Hologic (HOLX), Teleflex (TFX) and Abiomed (ABMD).
View all of DXCM's competitors.

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), salesforce.com (CRM), ServiceNow (NOW), The Walt Disney (DIS), The Trade Desk (TTD) and Shopify (SHOP).

What is DexCom's stock symbol?

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

Who are DexCom's major shareholders?

DexCom's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.60%), Baillie Gifford & Co. (5.39%), Artisan Partners Limited Partnership (2.04%), Lone Pine Capital LLC (1.93%), Nuveen Asset Management LLC (1.89%) and Geode Capital Management LLC (1.81%). Company insiders that own DexCom stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Bridgette P Heller, Chad Patterson, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends for DexCom.

Which institutional investors are selling DexCom stock?

DXCM stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Lone Pine Capital LLC, Capital International Investors, Compagnie Lombard Odier SCmA, Neuberger Berman Group LLC, Parallax Volatility Advisers L.P., Baillie Gifford & Co., and Los Angeles Capital Management LLC. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Bridgette P Heller, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven Robert Pacelli, and Sumi Shrishrimal.
View insider buying and selling activity for DexCom or view top insider-selling stocks.

Which institutional investors are buying DexCom stock?

DXCM stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Clearbridge Investments LLC, Amundi, Geode Capital Management LLC, Rathbone Brothers plc, Waycross Partners LLC, Marathon Asset Management LLP, and Ownership Capital B.V..
View insider buying and selling activity for DexCom or or view top insider-buying stocks.

How do I buy shares of DexCom?

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DexCom's stock price today?

One share of DXCM stock can currently be purchased for approximately $560.74.

How much money does DexCom make?

DexCom has a market capitalization of $54.25 billion and generates $1.93 billion in revenue each year. The medical device company earns $493.60 million in net income (profit) each year or $3.10 on an earnings per share basis.

How many employees does DexCom have?

DexCom employs 5,500 workers across the globe.

Does DexCom have any subsidiaries?

The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.

When was DexCom founded?

DexCom was founded in 1999.

What is DexCom's official website?

The official website for DexCom is www.dexcom.com.

Where are DexCom's headquarters?

DexCom is headquartered at 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121.

How can I contact DexCom?

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at (858) 200-0200 or via email at [email protected].